Overview

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This study is being done to investigate the impact of changing immunosuppressive medications from tacrolimus (Prograf®) to sirolimus (Rapamune®) between 6 and 24 months post transplant. The primary purpose of this research study is to evaluate whether the use of mycophenolate mofetil(MMF)/Cellcept® and tacrolimus(TAC)/Prograf® (Group 1) or mycophenolate mofetil(MMF)/Cellcept® and sirolimus/Rapamune® (Group 2) impacts the incidence of acute cellular rejection in post kidney transplant patients. This study will examine whether switching from tacrolimus to sirolimus will better preserve long-term kidney function.
Phase:
Phase 4
Details
Lead Sponsor:
Northwestern University
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Calcineurin Inhibitors
Everolimus
Mycophenolate mofetil
Sirolimus
Tacrolimus